PDCD1 and non-small cell lung carcinoma: 18F-BMS-986192 (18Fluor-labelled anti-PD-L1 Adnectin) uptake on positron emission tomography (PET) has been shown to correlate with PD-L1 expression in NSCLC, as has 89Zirconium-nivolumab for PD-1 expression, both in early phase clinical trials [13].